Bell Potter Sees 56-92% Upside Across Three ASX Picks: Biotech, Cybersecurity Small-Cap, and Mid-Cap Buy

The Quick Take

• Bell Potter issued bullish calls on three ASX-listed stocks Thursday, with upside targets ranging from 56% to 92% across biotech, cybersecurity, and a mid-cap buy signal.
• An ASX-listed cybersecurity small-cap could rise 92% according to Bell Potter, driven by high demand for its expertise in a sector seeing accelerating enterprise security spend globally.
• An ASX biotech with US market exposure could re-rate 56% higher, with Bell Potter identifying the American clinical or commercial market as the primary catalyst for value unlocking.

Bell Potter, one of Australia active mid-market equity research brokers, issued a cluster of bullish calls across three disparate ASX-listed names, a pattern that signals broad-based optimism in small-to-mid-cap Australian equities. The 92% upside target for a cybersecurity small-cap reflects the structural demand tailwind in enterprise security spending — Australian companies that have built genuine differentiation in threat detection or cloud security command premium valuations as global acquirers scan for intellectual property. The biotech 56% rerating thesis rests on US market catalyst optionality, a well-documented pattern where ASX biotechs are undervalued domestically until a US clinical read-out or regulatory event forces institutional re-engagement.

Bell Potter simultaneous coverage across biotech, cybersecurity, and a mainstream ASX 200 constituent carries index-linked implications. A 92% target on a cybersecurity name implies substantial institutional conviction in a segment that has benefited from rising corporate spend on identity management, endpoint protection, and cloud security — sectors where Australian vendors have found competitive niches. The biotech US market catalyst aligns with the well-established AUD/USD sensitivity dynamic: rerating events in USD-denominated markets amplify domestic returns when translated back through a weakened Australian dollar. The unspecified ASX 200 buy signal points to momentum building in a mainstream constituent, carrying passive fund buying implications.

For the biotech, the rerating timeline is defined by US clinical trial or regulatory event schedules — any FDA milestone or US commercial announcement is the primary catalyst Bell Potter is flagging. For the cybersecurity small-cap, enterprise contract wins and annual recurring revenue growth disclosed at the next earnings or investor day will confirm the 92% thesis. Macro variables include the AUD/USD exchange rate — both names with US exposure improve in Australian dollar terms when the currency weakens — and overall ASX risk appetite, which historically tracks the S&P 500 with a short lag on risk-on sessions like Thursday.

Synthesized from 3 sources.